Hypogonadism screening: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men | According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men who present with [[erectile dysfunction]], [[infertility]], [[HIV]], and young patients with [[Osteoporosis (patient information)|osteoporosis]]. | ||
==Screening== | ==Screening== | ||
Revision as of 17:26, 3 October 2017
|
Hypogonadism Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypogonadism screening On the Web |
|
American Roentgen Ray Society Images of Hypogonadism screening |
|
Risk calculators and risk factors for Hypogonadism screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ahmed Elsaiey, MBBCH [2]
Overview
According to the endocrine society, screening for hypogonadism is not recommended as it is not cost-effective. Hypogonadism screening may be done in order to diagnose the disease early and provide the appropriate treatment. Screening may be done for men who present with erectile dysfunction, infertility, HIV, and young patients with osteoporosis.
Screening
Screening for hypogonadism is not recommended by the endocrine society as it is not cost-effective. However, it may be performed in men who are thought to be at high risk of having hypogonadism. Screening is performed in men showing the following:[1][2]
- Erectile dysfunction
- Infertility
- HIV infected individuals
- Men who got exposed to radiation on the brain
- Young patients with osteoporosis.
References
- ↑ Ross A, Bhasin S (2016). "Hypogonadism: Its Prevalence and Diagnosis". Urol Clin North Am. 43 (2): 163–76. doi:10.1016/j.ucl.2016.01.002. PMID 27132573.
- ↑ Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS; et al. (2010). "Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 95 (6): 2536–59. doi:10.1210/jc.2009-2354. PMID 20525905.